Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools (NASDAQ: LAB) has announced its participation in three major investor conferences in March 2025. The company will present at TD Cowen's 45th Annual Healthcare Conference on March 3rd at 3:10 p.m. ET, attend investor meetings at the 2025 Leerink Partners Global Healthcare Conference on March 12th, and present at KeyBanc's 5th Annual Healthcare Forum on March 19th at 4:30 p.m. ET.
All presentations will be available via webcast on the company's Investor Relations website, with recordings archived at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) ha annunciato la sua partecipazione a tre importanti conferenze per investitori a marzo 2025. L'azienda presenterà al 45° Annual Healthcare Conference di TD Cowen il 3 marzo alle 15:10 ET, parteciperà a incontri con investitori al 2025 Leerink Partners Global Healthcare Conference il 12 marzo e presenterà al 5° Annual Healthcare Forum di KeyBanc il 19 marzo alle 16:30 ET.
Tutte le presentazioni saranno disponibili in webcast sul sito web delle Relazioni con gli Investitori dell'azienda, con registrazioni archiviate su investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) ha anunciado su participación en tres importantes conferencias para inversores en marzo de 2025. La empresa presentará en el 45° Annual Healthcare Conference de TD Cowen el 3 de marzo a las 3:10 p.m. ET, asistirá a reuniones con inversores en el 2025 Leerink Partners Global Healthcare Conference el 12 de marzo y presentará en el 5° Annual Healthcare Forum de KeyBanc el 19 de marzo a las 4:30 p.m. ET.
Todas las presentaciones estarán disponibles a través de webcast en el sitio web de Relaciones con Inversores de la empresa, con grabaciones archivadas en investors.standardbio.com.
표준 생명공학 (NASDAQ: LAB)은 2025년 3월에 열리는 세 가지 주요 투자자 회의에 참여한다고 발표했습니다. 회사는 3월 3일 오후 3시 10분 ET에 TD Cowen의 제45회 연례 헬스케어 회의에서 발표하고, 3월 12일에 2025 Leerink Partners 글로벌 헬스케어 회의에서 투자자 미팅에 참석하며, 3월 19일 오후 4시 30분 ET에 KeyBanc의 제5회 연례 헬스케어 포럼에서 발표할 예정입니다.
모든 발표는 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 녹화된 내용은 investors.standardbio.com에 보관됩니다.
Standard BioTools (NASDAQ: LAB) a annoncé sa participation à trois grandes conférences pour investisseurs en mars 2025. L'entreprise présentera lors de la 45e Conférence annuelle sur la santé de TD Cowen le 3 mars à 15h10 ET, assistera à des réunions avec des investisseurs lors de la 2025 Leerink Partners Global Healthcare Conference le 12 mars et présentera lors du 5e Forum annuel sur la santé de KeyBanc le 19 mars à 16h30 ET.
Toutes les présentations seront disponibles en webcast sur le site web des Relations avec les Investisseurs de l'entreprise, avec des enregistrements archivés sur investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) hat seine Teilnahme an drei wichtigen Investorenkonferenzen im März 2025 angekündigt. Das Unternehmen wird am 3. März um 15:10 Uhr ET beim 45. jährlichen Gesundheitskonferenz von TD Cowen präsentieren, an Investorenmeetings beim 2025 Leerink Partners Global Healthcare Conference am 12. März teilnehmen und am 19. März um 16:30 Uhr ET beim 5. jährlichen Gesundheitsforum von KeyBanc präsentieren.
Alle Präsentationen werden über Webcast auf der Investor Relations-Website des Unternehmens verfügbar sein, mit aufgezeichneten Inhalten, die auf investors.standardbio.com archiviert werden.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences:
- TD Cowen’s 45th Annual Healthcare Conference - March 3rd – 5th, 2025
Presenting on Monday, March 3, 2025, at 3:10 p.m. ET - 2025 Leerink Partners Global Healthcare Conference - March 9th – 12th, 2025
Participating in investor meetings on March 12th - KeyBanc’s 5th Annual Healthcare Forum – March 18th & 19th, 2025
Presenting on Wednesday, March 19, 2025, at 4:30 p.m. ET
Presentations will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2025 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact
David Holmes
ir@standardbio.com

FAQ
When is Standard BioTools (LAB) presenting at TD Cowen's Healthcare Conference in March 2025?
Which investor conferences will Standard BioTools (LAB) attend in March 2025?
How can investors access Standard BioTools (LAB) conference presentations?